Patents by Inventor Mi-Jin O.

Mi-Jin O. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Eye drops in form of solution comprising benzopyran derivative or pharmaceutically acceptable salt thereof
    Patent number: 11771647
    Abstract: The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: October 3, 2023
    Assignee: HANLIM PHARMACEUTICAL CO., LTD.
    Inventors: Dong-Yeop Shin, Hu-Seong Kim, Geun-Hyeog Lee, Kyung-Joon Kim, Yun-Seok Cho, Mi-Jin O, Mi-Jung Kim
  • EYE DROPS IN FORM OF SOLUTION COMPRISING BENZOPYRAN DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20200405634
    Abstract: The present invention provides an eye drop formulation in the form of a solution, comprising (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof; propylene glycol as a stabilizing agent; and a pH controlling agent in an aqueous medium, wherein the eye drop formulation has a pH ranging from 4.0 to 5.0. The eye drop formulation of the present invention can contain (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran or a pharmaceutically acceptable salt thereof in a high concentration; and has an excellent stability. In addition, the pharmaceutical product for preventing or treating macular degeneration according to the present invention can be stored for extended periods.
    Type: Application
    Filed: February 18, 2019
    Publication date: December 31, 2020
    Applicant: HANLIM PHARMACEUTICAL CO., LTD.
    Inventors: Dong-Yeop SHIN, Hu-Seong KIM, Geun-Hyeog LEE, Kyung-Joon KIM, Yun-Seok CHO, Mi-Jin O, Mi-Jung KIM
  • Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration
    Patent number: 8859531
    Abstract: The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: October 14, 2014
    Assignee: Hanlim Pharmaceutical Co., Ltd
    Inventors: Sang-Yong Lee, Geun-Hyeog Lee, Byong-Sun Choi, Jong-Hyeon Ryu, Jin-Ha Park, Mi-Jin O
  • PHARMACEUTICAL COMPOSITION INCLUDING MOMETASONE FUROATE AND AZELASTINE HYDROCHLORIDE FOR NASAL ADMINISTRATION
    Publication number: 20130252929
    Abstract: The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.
    Type: Application
    Filed: November 18, 2011
    Publication date: September 26, 2013
    Applicant: HANLIM PHARMACEUTICAL CO., LTD.
    Inventors: Sang-Yong Lee, Geun-Hyeog Lee, Byong-Sun Choi, Jong-Hyeon Ryu, Jin-Ha Park, Mi-Jin O.